By Barbara Obstoj-Cardwell. Editor
M&A news last week featured US pharma giant Merck & Co announcing it plans to acquire Prometheus Biosciences, in a cash deal worth $10.8 billion, aiming to strengthen its immunology pipeline. Also of note, the UK’s GSK, looking to replenish its portfolio, is buying Canadian firm Bellus Health, along with its chronic cough product camlipixant, for $2 billion. In other news, some important research was presented at the American Association of Cancer Research (AAC) by Moderna on mRNA-4157, its neoantigen immunotherapy. Also, US health care giant Johnson & Johnson, always the first big pharma to release quarterly financials, reported first quarter figures much in line with expectations, but its shares fell due to certain other disclosures.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze